FSA Wealth Management LLC Makes New $58,000 Investment in Becton, Dickinson and Company (NYSE:BDX)

FSA Wealth Management LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, Holdings Channel reports. The firm purchased 241 shares of the medical instruments supplier’s stock, valued at approximately $58,000.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Livelsberger Financial Advisory bought a new stake in Becton, Dickinson and Company during the third quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $33,000. Tompkins Financial Corp boosted its position in shares of Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the period. Sound Income Strategies LLC grew its holdings in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Finally, Opal Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 2nd quarter valued at approximately $45,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BDX has been the subject of a number of analyst reports. Evercore ISI boosted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $221.90 on Monday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average of $234.16 and a two-hundred day moving average of $234.10. The company has a market capitalization of $64.14 billion, a price-to-earnings ratio of 37.36, a PEG ratio of 1.65 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.42 earnings per share. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company’s payout ratio is presently 63.97%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.